Adial Pharmaceuticals, Inc. (ADIL)
Nasdaq · Healthcare · Biotechnology
$4.35+5.58%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $11.4M
- 52-week range
- $1.31 – $10.75
- 52-week change
- −57.74%
- EPS (trailing)
- −$20.65
Fiscal year to Dec 2025
- Net income
- −$7.98T
- Diluted EPS
- −$11.93
From the company’s annual report on SEC EDGAR.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Headquarters: Glen Allen, United States · 5 employees · adial.com